- Home
- RXRX vs TVTX Comparison
RXRX vs TVTX Comparison
Compare RXRX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- TVTX
- Stock Information
- Founded
- RXRX 2013
- TVTX 2008
- Country
- RXRX United States
- TVTX United States
- Employees
- RXRX N/A
- TVTX N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- TVTX Health Care
- Exchange
- RXRX Nasdaq
- TVTX Nasdaq
- Market Cap
- RXRX 2.6B
- TVTX 2.5B
- IPO Year
- RXRX 2021
- TVTX N/A
- Fundamental
- Price
- RXRX $5.52
- TVTX $35.16
- Analyst Decision
- RXRX Buy
- TVTX Strong Buy
- Analyst Count
- RXRX 4
- TVTX 16
- Target Price
- RXRX $7.25
- TVTX $35.20
- AVG Volume (30 Days)
- RXRX 69.9M
- TVTX 2.0M
- Earning Date
- RXRX 11-05-2025
- TVTX 10-30-2025
- Dividend Yield
- RXRX N/A
- TVTX N/A
- EPS Growth
- RXRX N/A
- TVTX N/A
- EPS
- RXRX N/A
- TVTX N/A
- Revenue
- RXRX $64,596,000.00
- TVTX $435,826,000.00
- Revenue This Year
- RXRX $24.17
- TVTX $83.23
- Revenue Next Year
- RXRX $20.96
- TVTX $41.49
- P/E Ratio
- RXRX N/A
- TVTX N/A
- Revenue Growth
- RXRX 30.14
- TVTX 114.22
- 52 Week Low
- RXRX $3.79
- TVTX $12.91
- 52 Week High
- RXRX $12.36
- TVTX $35.34
- Technical
- Relative Strength Index (RSI)
- RXRX 47.68
- TVTX 85.39
- Support Level
- RXRX $5.58
- TVTX $26.79
- Resistance Level
- RXRX $6.50
- TVTX $30.97
- Average True Range (ATR)
- RXRX 0.57
- TVTX 1.22
- MACD
- RXRX -0.08
- TVTX 0.38
- Stochastic Oscillator
- RXRX 21.33
- TVTX 98.15
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.